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ABSTRACT
Introduction: An alternative formulation of 0.5% 
moxifloxacin ophthalmic solution (Moxeza®, 
MOXI-AF, Alcon Laboratories, Inc., Fort Worth, 
TX, USA) containing xanthan gum to prolong 
retention on the eye has been developed. 
MOXI-AF was designed to optimize the 
treatment regimen for bacterial conjunctivitis for 
the convenience of the patient with twice-daily 
dosing. Methods: A safety and efficacy clinical 
study was conducted as a multicenter, vehicle-
controlled, randomized, double-masked, parallel 
group study in clinically diagnosed bacterial 
conjunctivitis patients aged >28 days. MOXI-AF 
or its vehicle was dosed one drop twice-daily for 
3 days. Microbiological specimens were obtained 
from affected eyes on day 1, prior to the initial 
dose, and on day 4 after 3 days of dosing, and 
processed using routine clinical microbiology 
laboratory methods. All recovered bacteria were 
identified to the species level. Results: This 
paper reports on the microbiological success 
rate, a secondary efficacy variable in the trial. All 
patients (1180) were randomized to treatment. 
Patient age ranged from 30 days to 92 years. 
The microbiological success rate for patients 
treated topically with MOXI-AF twice-daily 
for 3 days was 74.5%, compared with 56.0% 
of patients treated with its vehicle control 
(P<0.0001). MOXI-AF was also statistically 
more effective than vehicle in eradicating 
the three principle conjunctivitis pathogens, 
Haemophilus influenzae (98.5% vs. 59.6%, 
respectively), Streptococcus pneumoniae (86.4% 
vs. 50.0%, respectively), and Staphylococcus 
aureus (94.1% vs. 80.0%, respectively) (P<0.001). 
Conclusion: The xanthan gum-based 0.5% 
moxifloxacin ophthalmic formulation, 
MOXI-AF, provides effective eradication of the 
three principle causative pathogens of bacterial 
conjunctivitis across all age groups when dosed 
twice-daily for 3 days.
Keywords :  bac te r i a l  conjunct iv i t i s ; 
f luoroquinolone;  microbia l  e f f icacy ; 
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INTRODUCTION 
The most common ocular infection seen by 
general practitioners is bacterial conjunctivitis.1 
It is highly contagious and often transferred to 
the other eye or to another individual by contact. 
More than half of all red eye cases in young 
children can be attributed to bacterial pathogens,2
the most common being Haemophilus influenzae 
and Streptococcus pneumoniae. 
Moxifloxacin hydrochloride is a fourth 
generation fluoroquinolone developed as tablet 
and intravenous formulations (AVELOX®, 
Bayer-Schering Pharma AG, Berlin, Germany) 
for the treatment of various infections, 
including community-acquired pneumonia, 
acute exacerbation of chronic bronchitis, 
acute sinusitis, and uncomplicated skin and 
skin structure infections. In 2003, a topical 
ophthalmic formulation of moxifloxacin, 
VIGAMOX® (moxifloxacin hydrochloride 
ophthalmic solution 0.5% as base, Alcon 
Laboratories, Inc., Fort Worth, TX, USA), was 
approved, and is marketed for the treatment of 
bacterial conjunctivitis in the US. The approved 
dosage and administration for VIGAMOX is one 
drop in the affected eye 3 times a day (TID) for 
7 days.
An alternative formulation of 0.5% 
moxifloxacin ophthalmic solution (Moxeza®, 
MOXI-AF, Alcon Laboratories, Inc., Fort Worth, 
TX, USA) containing xanthan gum to prolong 
retention on the eye has been developed. 
MOXI-AF was designed to improve the 
treatment regime of bacterial conjunctivitis for 
the convenience of the patient by reducing the 
dosing frequency compared with VIGAMOX 
(twice-daily [BID] versus TID). This is the first 
report of results from a phase 3 clinical trial 
designed to demonstrate the safety and efficacy 
of MOXI-AF for the treatment of bacterial 
conjunctivitis. This paper reports on the 
microbiological success rate, a secondary efficacy 
variable of the clinical study. 
METHODS
Study Design
This clinical study was designed as a multicenter, 
vehicle-controlled, randomized, double-masked, 
parallel group study (NCT00759148) conducted 
in accordance with Good Clinical Practices, the 
Declaration of Helsinki, and Health Insurance 
Portability and Accountability Act (HIPAA) 
guidelines. All study sites received approval 
from their respective institutional review boards 
or independent ethics committees. Prior to 
performing any study screening procedures, 
every patient or legally authorized representative 
(ie, parent or guardian) provided signed 
informed consent. 
Patients
Patients were >28 days old and had a clinical 
diagnosis of bacterial conjunctivitis in one or 
both eyes based on bulbar conjunctival injection 
and discharge (minimum score of 1 on a 
4-point scale for each sign) and matting. Patient 
eligibility was independent of a positive bacterial 
culture at day 1. Patients were excluded from 
the study if signs and symptoms of bacterial 
conjunctivitis had begun longer than 4 days 
prior to the first visit. 
Treatment
Eligible patients were randomized in a 1:1 ratio 
to treatment with MOXI-AF or vehicle. To 
maintain masking, specifically designated site 
personnel other than the study investigator 
instilled the first dose of medication at the day 1 
visit. Patients received one drop of MOXI-AF or 
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vehicle in the conjunctival sac of both eyes BID 
(morning and evening) for 3 days (a total of six 
drops per eye). Patients were evaluated clinically 
at three scheduled visits: day 1 (screening/
baseline), day 3, and day 4 (end of therapy 
visit). The last visit took place 12-48 hours after 
administration of the last dose. 
Microbiological Specimens - Collection and 
Processing 
Two microbiology swab specimens, the first swab 
for recovery of bacteria isolates and the second 
for polymerase chain reaction (PCR) detection of 
adenovirus and Chlamydia, were collected from 
patients’ affected eyes before administration of 
the study medication at day 1. Microbiological 
specimens were also collected on day 4, after 
3 days of therapy or at any time a patient was 
declared a treatment failure by the investigator. 
Microbiological specimens were shipped 
overnight to a central laboratory (Eurofins 
Medinet, Inc., Chantilly, VA, USA) and were 
processed within 24-72 hours of collection. For 
the first swab, standard microbiology methods 
were used for recovery and purification of 
bacterial isolates. Characterization of each 
bacterial isolate to the species and strain level 
included, as appropriate, both phenotypic 
testing (Gram staining, VITEK® AutoMicrobic 
System, bioMérieux, Inc., Durham, NC, USA, or 
API® biochemical test strips, bioMérieux, Inc., 
Durham, NC, USA) and genotypic methods 
(RiboPrinter® Microbial Characterization System, 
DuPont Qualicon, Wilmington, DE, USA, and/
or sequence analysis of the 16S rRNA gene 
using MicroSeq® software and reagents, Applied 
Biosystems, Carlsbad, CA, USA). 
Actual recovery methodology was not used 
for adenovirus and Chlamydia spp. Instead, 
total DNA was extracted from the second 
swab specimen using the QIAamp® DNA Mini 
Kit (Qiagen, Valencia, CA, USA). PCR was 
subsequently performed on these DNA extracts 
to detect either adenovirus or Chlamydia. 
Analysis of the Microbiological Variables 
The intent-to-treat (ITT) dataset includes all 
randomized patients who received treatment. 
Only those ITT patients from whose affected 
eye(s) bacteria were recovered on day 1 were 
included in the microbiological intent-to-treat 
(MBITT) dataset. The modified per protocol 
(MPP) dataset included only those MBITT 
patients who finished the study; that is, 
completed an exit visit and complied with all 
conditions of the study protocol. 
Microbiological Efficacy by Patient
The patient level microbiological efficacy 
outcome was based on the response of one eye, 
the “worst eye” or “study eye” on day 1. In the 
case that both eyes were affected and the clinical 
signs and symptoms were the same, the right 
eye was chosen as the “study eye” for analysis. 
A patient was declared a microbiological success 
if all pretherapy bacterial isolate(s) recovered 
were eradicated from the “study eye” specimen 
at the day 4 exit visit. A patient was declared 
a microbiological failure if: a) any of the day 1 
bacterial strains were recovered from the “study 
eye” specimen at the day 4 exit visit; b) bacterial 
strains were recovered from the “study eye” at 
an exit specimen from a patient with unresolved 
clinical signs or symptoms. 
Microbiological Eradication by Species
Another measure of effectiveness of the 
therapy is to examine the ability of the 
therapy to eradicate specific bacterial species in 
conjunctivitis. The bacterial species eradication 
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rate was calculated by dividing the number 
of eradicated isolates of a particular species 
by the total number of isolates of that species 
(eradicated plus persisting isolates), multiplied 
by 100. For purposes of this calculation, 
eradicated isolates in the “study eye” of a 
patient declared as a microbiological failure 
were not counted because of the clinical failure.
RESULTS
Study Population
The overall study population demographics 
are presented in Table 1. Patients ranged in age 
from 30 days to 92 years. For all demographic 
categories, the distribution of patients in the two 
treatment arms was comparable. A total of 1180 
patients were enrolled and randomized in the 
study from October 2008 to March 2010 from 
82 investigational sites and 27 states across the 
United States. There were 1179 evaluable patients 
in the ITT dataset and 847 evaluable patients in 
the MBITT dataset, 424 treated with MOXI-AF 
and 423 treated with vehicle. There were 769 
evaluable patients in the MPP dataset, 385 treated 
with MOXI-AF and 384 treated with vehicle. 
Microbiological Efficacy by Patient
The microbiological efficacy success rate is 
presented in Table 2. In the MBITT dataset, 
74.5% of the patients treated BID for 3 days 
with MOXI-AF were microbiological successes, 
compared with 56.0% for patients treated with 
vehicle (P<0.0001). 
Microbiological Eradication by Species
The eradication rate for each of the three 
principle bacterial conjunctivitis pathogens 
(H. influenzae, S. pneumoniae, and Staphylococcus 
aureus) for both the MBITT and MPP data 
sets is presented in Table 3. H. influenzae
and S. pneumoniae are also recognized as 
major respiratory pathogens. MOXI-AF was 
significantly more effective than vehicle in 
eradicating the three principle conjunctivitis 
pathogens, H. influenzae (98.5% vs. 59.6%, 
respectively), S. pneumoniae (86.4% vs. 50.0%, 
respectively), and S. aureus (94.1% vs. 80.0%, 
respectively) (P<0.001).
In Table 4, the frequency of occurrence of 
the three principle pathogens as a function of 
Overall study population
MOXI-AF Vehicle
Patients, n 593 586
Age, n (%)*
28 days-23 months 49 (8.3) 47 (8.0)
2-11 years 174 (29.3) 184 (31.4)
12-17 years 71 (12.0) 72 (12.3)
18-64 years 257 (43.3) 230 (39.2)
≥65 years 42 (7.1) 53 (9.0)
Sex, n (%)
Male 240 (40.5) 248 (42.3)
Female 353 (59.5) 338 (57.7)
Race, n (%)
White 463 (78.1) 488 (83.3)
Black or African 
American
84 (14.2) 55 (9.4)
Asian 18 (3.0) 8 (1.4)
Native Hawaiian 3 (0.5) 1 (0.2)
American Indian 6 (1.0) 6 (1.0)
Other 14 (2.4) 21 (3.6)
Multiracial 5 (0.8) 7 (1.2)
Ethnicity, n (%)
Hispanic, Latino or 
Spanish
141 (23.8) 152 (25.9)
Not Hispanic, Latino 
or Spanish
452 (76.2) 434 (74.1)
*Actual age range: 30 days-92 years
Table 1. Patient demographics at baseline.
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patient age is presented. These bacterial species 
were not recovered equally among conjunctivitis 
patients of various age groups. H. influenzae and
S. pneumoniae infections were more common 
in younger patients (<12 years of age). S. aureus
was recovered from one in four patients who 
were ≥65 years of age, which is approximately 
three times the frequency of other age groups. 
Considering the number of patients affected for 
each age group, combined with the eradication 
rate for these three species, MOXI-AF was shown 
to be equally active across all age groups.
Microbiology of Conjunctivitis
A total of 1700 bacterial isolates were 
recovered from the affected eyes of 1180 









n % P value
MBITT 424 316 74.5 423 237 56.0 <0.0001
MPP 385 285 74.0 384 220 57.3 <0.0001
MBITT=microbiological intent-to-treat population; MPP=modified per protocol population.














H. influenzae 177 (20.9%) 48 (55.2%) 92 (35.0%) 4 (4.5%) 28 (8.4%) 5 (6.7%)
S. pneumoniae 74 (8.7%) 14 (16.1%) 32 (12.2%) 7 (8.0%) 17 (5.1%) 4 (5.3%)
S. aureus 67 (7.9%) 2 (2.3%) 22 (8.4%) 4 (4.5%) 22 (6.6%) 17 (22.7%)











H. influenzae 67 66 98.5 52 31 59.6
S. pneumoniae 22 19 86.4 18 9 50.0
S. aureus 17 16 94.1 15 12 80.0
MPP
H. influenzae 60 60 100 47 29 61.7
S. pneumoniae 18 16 88.9 14 8 57.1
S. aureus 16 15 93.8 14 11 78.6
MBITT=microbiological intent-to-treat population; MPP=modified per protocol population
Table 3. Eradication rate by species at day 4.
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Table 5. Bacteria recovered from conjunctivitis patients. 
MOXI-AF Vehicle
Total isolates (n=1305) 646 659
Gram-positive bacteria, n (%) 536 (83%) 540 (82%)
Actinomycetaceae
Actinomyces meyeri 1 0
Aerococcaceae
Aerococcus viridans 1 0
Bacillaceae
Bacillus cereus 1 1
Bacillus circulans 0 2
Bacillus licheniformis 1 1
Bacillus megaterium 1 0
Bacillus mycoides 1 0
Bacillus niacini 1 0
Bacillus pumilus 3 4
Bacillus species 2 0
Bacillus subtilis 1 1
Bacillus thuringiensis 1 0
Carnobacteriaceae
















Corynebacterium species 0 3
Corynebacterium striatum 0 1
Enterococcaceae
Enterococcus casseliflavus 0 1
Enterococcus faecalis 5 5
Enterococcus faecium 0 1
Enterococcus species 0 1
Microbacteriaceae
Microbacterium oxydans 1 0
Micrococcaceae
Kocuria rhizophila 1 0
MOXI-AF Vehicle
Total isolates (n=1305) 646 659
Gram-positive bacteria, n (%) 536 (83%) 540 (82%)
Rothia dentocariosa 1 0
Rothia mucilaginosa 2 1
Norcardiaceae
Rhodococcus species 1 0
Paenibacillaceae
Brevibacillus borstelensis 0 3
Brevibacillus laterosporus 0 1
Paenibacillus species 1 1
Propionibacteriaceae




Propionibacterium species 5 3
Staphylococcaceae
Dolosigranulum pigrum 1 1
Staphylococcus aureus 31 27
Staphylococcus capitis 39 48
Staphylococcus caprae 1 1
Staphylococcus epidermidis 142 140
Staphylococcus hemolyticus 1 0
Staphylococcus hominis 5 5
Staphylococcus pasteuri 1 1
Staphylococcus piscifermentans 1 0
Staphylococcus saprophyticus 3 0
Staphylococcus warneri 5 8
Streptococcaceae
Lactococcus lactis 1 2
Streptococcus cristatus 1 2
Streptococcus gordonii 2 0
Streptococcus mitis 17 16
Streptococcus oralis 1 5
Streptococcus parasanguinis 4 2
Streptococcus pneumoniae 35 33
Streptococcus salivarius 1 3
Streptococcus sanguis 2 2
Streptococcus species 4 9
Streptococcus viridans group 3 6
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10 days, and rarely lasting longer than 
3 weeks. Treatment is usually empiric using 
an antibiotic with broad coverage for the 
wide variety of conjunctivitis pathogens. 
Prompt, appropriate treatment reduces the 
time to disease resolution, minimizes the 
risk of sequelae, helps prevent the spread of 
infection, and reduces the time away from 
work or school.3-9 A Cochrane analysis of 
placebo-controlled clinical trials with broad-
spectrum topical antibiotics demonstrated 
the benefit of treatment in improving clinical 
and microbiological remission rates after 
2 to 5 days of treatment, and these advantages 
persisted, although reduced, through days 6 to 
10 of therapy.10
A total of 1305 isolates were recovered from 847 
study eyes (MBITT dataset) used for analysis. 
As shown in Table 5, 82% (1076/1305) of the 
isolates belonged to 58 Gram-positive species 
(17 genera) and 18% (229/1305) of the isolates 
belonged to 31 Gram-negative species (19 
genera) and the distribution of bacterial species 
was similar between the two treatment groups. 
In addition, adenovirus was detected in 15 of 
the 1180 patients, while Chlamydia was not 
detected in any patient.
DISCUSSION
Bacterial conjunctivitis is usually self-
limiting, with resolution after approximately 
MOXI-AF Vehicle
Total isolates (n=1305) 646 659
Gram-negative bacteria, n (%) 110 (17%) 119 (18%)
Moraxellaceae
Acinetobacter baumannii 0 1
Acinetobacter genospecies 3 0 1
Acinetobacter species 1 0
Acinetobacter ursingii 1 0
Moraxella catarrhalis 1 2
Moraxella lacunata 0 2
Neisseriaceae
Neisseria meningitidis 0 1
Pasteurellaceae
Haemophilus influenzae 82 84
Pseudomonadaceae
Pseudomonas aeruginosa 2 2
Pseudomonas species 1 0
Sphingomonadaceae
Sphingomonas species 0 1





Total isolates (n=1305) 646 659
Gram-negative bacteria, n (%) 110 (17%) 119 (18%)
Comamonadaceae
Acidovorax temperans 3 1
Enterobacteriaceae
Citrobacter koseri 1 0
Enterobacter aerogenes 0 1
Enterobacter cloacae 1 0
Enterobacter hormaechei 1 2
Enterobacter species 0 2
Escherichia coli 2 1
Klebsiella oxytoca 0 1
Klebsiella ozaenae 0 1
Klebsiella pneumoniae 1 4
Pantoea species 0 2
Proteus mirabilis 1 4
Proteus vulgaris 1 0
Raoultella ornithinolytica 0 1
Serratia marcescens 4 1
Flavobacteriaceae
Chryseobacterium indologenes 3 0
Elizabethkingia miricola 1 0
Terrimonas species 0 1
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In this large multicenter study with 
investigators spread across the United States, 
the isolates recovered prior to the initiation 
of therapy provide a comprehensive picture of 
the diverse nature of microorganisms that can 
be associated with bacterial conjunctivitis. The 
spectrum of bacteria recovered is considered 
typical for bacterial conjunctivitis patients.11,12 
Most topical ophthalmic antibiotic products 
approved in the United States for the treatment 
of bacterial conjunctivitis have a 7- to 10-day 
treatment regimen, totaling a minimum of 21-42 
or more drops over a course of therapy. A full 
course of therapy with MOXI-AF is 14 drops over 
7 days. Results from this study demonstrate that 
MOXI-AF, when dosed topically BID for 3 days 
(total six drops per eye), was statistically superior 
to its vehicle in the percentage of patients 
classified as microbiological successes after 
3 days of treatment (75% vs. 56%, P<0.0001). 
MOXI-AF was also significantly more effective 
than its vehicle in eradicating the three principle 
conjunctivitis pathogens. The eradication rate 
of H. influenzae was 98.5% for MOXI-AF versus 
59.6% for its vehicle; S. pneumoniae was 86.4% 
for MOXI-AF compared with 50.0% for vehicle, 
and S. aureus was 94.1% for MOXI-AF compared 
with 80.0% for vehicle.
CONCLUSION
These microbiological eradication data 
demonstrated that MOXI-AF provided effective 
eradication of bacterial pathogens following 
3 days of treatment for bacterial conjunctivitis. 
The convenience of the simplified BID dosing 
regimen and the rapid eradication of the 
most common causative pathogens may be 
expected to allow earlier return to daycare 
or school for children as young as 1 month 
old, without risk of spreading the infection 
to others. 
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